AMRX
Amneal Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow +0.4% ·
net new positions -10.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | -4 | 106.56M | $1.84B | +7 | −10 |
| Q1 2026 | 107 | -1 | 100.53M | $1.25B | +9 | −11 |
| Q4 2025 | 109 | 0 | 106.30M | $1.34B | +1 | — |
| Q3 2025 | 18 | 0 | 61.16M | $612.26M | — | — |
| Q2 2025 | 15 | -1 | 52.63M | $425.79M | — | −1 |
| Q1 2025 | 13 | +3 | 21.14M | $177.14M | +3 | — |
| Q4 2024 | 10 | -1 | 20.64M | $163.48M | — | −1 |
| Q3 2024 | 10 | 0 | 16.87M | $140.36M | +2 | −2 |
| Q2 2024 | 10 | — | 16.56M | $105.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 8.98M | +1.0% | $71.13M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 8.98M | +1.0% | $71.13M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.81M | +0.7% | $30.21M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 3.81M | +0.7% | $30.21M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 3.70M | — | $29.29M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 1.54M | -25.5% | $12.21M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 1.32M | +62.0% | $10.49M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 686.50K | -9.2% | $5.44M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 336.80K | +11.1% | $2.67M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 336.80K | +11.1% | $2.67M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 336.80K | +11.1% | $2.67M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 97.25K | +11.1% | $771,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 87.88K | +84.4% | $696,033 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 74.02K | -10.4% | $586,230 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 74.02K | -10.4% | $586,230 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Wellington Management ✦ | 74.02K | -10.4% | $586,230 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Wellington Management ✦ | 74.02K | -10.4% | $586,230 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $226,678 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 314 holders, 158.91M shares, $1.92B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $882,000
Officer · 146.40K sh · $2.56M
Officer · 210.00K sh · $3.65M
Officer · 6.61K sh · $117,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
17.6% of class · View original SEC filing ↗
8.4% of class · View original SEC filing ↗
9.4% of class · View original SEC filing ↗